Dear Client,
As part of our ongoing commitment to ensuring the security of your online trading experience, we would like to inform you of our protocol for addressing any suspicious activities observed on your trading account
Should you notice any irregularities or suspect unauthorized access to your account, we kindly request that you take immediate action by following the steps outlined below:
Send an Email Please send an email to stoptrade@acml.in from your registered email ID. In the email, briefly outline the suspicious activity you have observed.
Phone Call Alternatively, you can call us at 07968101000 Ext: 1 from your registered mobile number. This will enable us to address your concerns promptly.
When contacting us, please ensure you provide the following details:
By providing this information, you enable us to swiftly investigate and take appropriate measures to safeguard your account.
Your security and peace of mind are of utmost importance to us, and we appreciate your cooperation in maintaining the integrity of your trading account.
The agency has also affirmed the company's short term rating at '[ICRA] A1+'.
ICRA stated that the rating action factors in Indraprastha Medical Corporation Limited (IMCL)'s established presence and strong market position in the NCR region, its healthy operating metrics and its robust financial profile.
The ratings also factor in IMCL's revenue diversification across specialities, including oncology, neurology, cardiology and nephrology, among others.
The financial risk profile remains comfortable as reflected by minimal gearing, robust debt protection indicators and a strong liquidity profile.
Further, the ratings factor in the strong parentage of Apollo Hospitals Enterprise Limited (AHEL) along with its promoters, holding a 25% stake in IMCL. The entity has significant operational, financial and managerial linkages with AHEL. Apollo Hospitals is among the leading healthcare players, operating one of the largest hospital chains in the country.
However, the ratings remain constrained by the geographical and asset concentration risks, as IMCL's operations are concentrated across two hospitals in the National Capital Region (NCR). Like other entities in the sector, IMCL remains exposed to regulatory risks, with previous restrictions imposed by various authorities.
The ratings also factor in the competitive pressures and the necessity to retain medical talent in an ever-evolving market.
Incorporated in 1988 as a JV between Apollo Hospitals Enterprise (AHEL) and the Delhi Government, Indraprastha Medical Corporation (IMCL) is a 749-bedded, super speciality tertiary care hospital in New Delhi and Noida.
The scrip gained 3.09% to currently trade at Rs 415.30 on the BSE.
Powered by Capital Market - Live News